Scholarlink

Background <p>Sentinel lymph node biopsy (SLNB) is crucial for staging malignant melanoma, but introduces additional risks and costs. This study aims to evaluate the quality and morbidity of SLNB at our institution.</p> Patients and Methods <p>We conducted a retrospective analysis of patients who underwent SLNB between 2017 and 2024. Patients were included if they underwent surgical treatment for melanoma and were evaluated for SLNB. Quality metrics included percentage of clinical stage Ib/II disease undergoing SLNB, node identification rate, and pathologic positivity rate. Morbidity was assessed, and the burden of care was determined by number of postoperative clinic visits.</p> Results <p>In total, 153 patients underwent SLNB with a mean age of 65 (30–96) years and a male:female ratio of 55:45. A sentinel node was identified in 150 patients (98.0%) with a mean of 1.89 nodes excised and metastases identified in 22 patients (14.7%). Complications occurred in 22 patients (14.4%), including seroma drainage (<i>n</i> = 15, 9.8%), wound infection (<i>n</i> = 5, 3.3%), hematoma (<i>n</i> = 3, 1.8%), and lymphedema (<i>n</i> = 4, 2.4%). Patients with SLN complications had more postoperative visits than those without complications (mean 2.38 versus 1.66, <i>p</i> = 0.0004). Patients undergoing SLNB with wide local excision (WLE) had more visits compared with WLE alone (mean 1.84 versus 1.23, <i>p</i> &lt; 0.0001).</p> Conclusions <p>SLNB is valuable for melanoma staging, with reliable identification and detection of metastases, but is associated with additional morbidity, which increases the burden of care. These findings may add value in deciding the merits of SLNB in patients with a lower risk of SLN metastases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Better-Defined Morbidity of Sentinel Lymph Node Biopsy in Patients with Melanoma

  • 期刊论文

  • 发表日期：

    2025年2月13日

查看全文
  • Mason Gonzales,
  • Kent Grosh,
  • Samuel Coster,
  • Amanda Hunt,
  • Christine Schmitt,
  • Megan Baxter,
  • Theresa McGoff,
  • Austin Brubaker,
  • Laurence E. McCahill

摘要

Background

Sentinel lymph node biopsy (SLNB) is crucial for staging malignant melanoma, but introduces additional risks and costs. This study aims to evaluate the quality and morbidity of SLNB at our institution.

Patients and Methods

We conducted a retrospective analysis of patients who underwent SLNB between 2017 and 2024. Patients were included if they underwent surgical treatment for melanoma and were evaluated for SLNB. Quality metrics included percentage of clinical stage Ib/II disease undergoing SLNB, node identification rate, and pathologic positivity rate. Morbidity was assessed, and the burden of care was determined by number of postoperative clinic visits.

Results

In total, 153 patients underwent SLNB with a mean age of 65 (30–96) years and a male:female ratio of 55:45. A sentinel node was identified in 150 patients (98.0%) with a mean of 1.89 nodes excised and metastases identified in 22 patients (14.7%). Complications occurred in 22 patients (14.4%), including seroma drainage (n = 15, 9.8%), wound infection (n = 5, 3.3%), hematoma (n = 3, 1.8%), and lymphedema (n = 4, 2.4%). Patients with SLN complications had more postoperative visits than those without complications (mean 2.38 versus 1.66, p = 0.0004). Patients undergoing SLNB with wide local excision (WLE) had more visits compared with WLE alone (mean 1.84 versus 1.23, p < 0.0001).

Conclusions

SLNB is valuable for melanoma staging, with reliable identification and detection of metastases, but is associated with additional morbidity, which increases the burden of care. These findings may add value in deciding the merits of SLNB in patients with a lower risk of SLN metastases.